Name:	MKC-231
Development Status:	investigational in U.S.
FDA Phase:	Inactive
Primary Medical Role:	May enhance the function of high-affinity choline uptake system and acetylcholine release in the central nervous system.
Role in Alzheimer's Disease:	Cholinergic signalling is sharply reduced early in the course of AD, MKC-231 may increase the amount of choline available to synthesize acetylcohline.
Contraindications:	n/a
Side Effects:	n/a
Companies:	Mitsubishi Tanabe Pharma
Notes:	MKC-231 development and testing in Alzheimer Disease has been discontinued, in favor of being tested for Depression and Anxiety disorders. This record last updated Dec 19, 2008.

References

Akaike A, Maeda T, Kaneko S, Tamura Y. Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons. Jpn J Pharmacol. 1998 Feb;76(2):219-22. Abstract

Bessho T, Takashina K, Tabata R, Ohshima C, Chaki H, Yamabe H, Egawa M, Tobe A, Saito K. Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1- yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b] quinolin- 4-yl)acetoamide on deficits of water maze learning in rats. Arzneimittelforschung. 1996 Apr;46(4):369-73. Abstract

Murai S, Saito H, Abe E, Masuda Y, Odashima J, Itoh T. MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice. J Neural Transm Gen Sect. 1994;98(1):1-13. Abstract